BC Investment plans to divest a 2% stake in Emcure Pharmaceuticals through a block deal valued at ₹493 Crore, indicating a strategic portfolio adjustment amidst robust company performance.
Target Company Overview
Emcure Pharmaceuticals Limited is a prominent player in the pharmaceutical sector, recognized for its innovative approach and robust product portfolio. The company has demonstrated significant financial growth, posting a consolidated net profit of ₹243 Crore for the quarter ending September 2025, representing a remarkable year-on-year increase of 25.10% from ₹194 Crore in the same quarter of the previous year.
Furthermore, the company reported an impressive revenue growth of 13.40% year-on-year, reaching ₹2,269.80 Crore in Q2 FY26, compared to ₹2,001.90 Crore in Q2 FY25. Emcure's consistent performance showcases its strong market position and ability to navigate the competitive landscape of the pharmaceutical industry.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in India
The pharmaceutical industry in India has emerged as a global hub for drug manufacturing and innovation. With a growing population and increasing healthcare needs, the demand
Similar Deals
Somerset → Cyrix Healthcare
2024
ADV Partners → Dr. Agarwal’s Healthcare Limited
Kedaara Capital → Vijaya Diagnostic Centre Private Limited
WhiteOak Capital, Creador, Siguler Guff → La Renon Healthcare
Quadria Capital → Maxivision Eye Hospital
BC Investment (Bain Capital)
invested in
Emcure Pharmaceuticals Limited
in 2025
in a Other Private Equity deal
Disclosed details
Transaction Size: $59M
Revenue: $273M
EBITDA: $57M
Net Income: $29M